Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors

Inclusion Criteria: * Patients ≤70 years old * Eligible diagnoses: * CML in AP * AML with high-risk cytogenetics \[del(5q)/-5, del(7q)/-7, abnormal 3q, 9q, 11q, 20q, 21q, 17p, t(6:9), t(9;22), complex karyotypes (≥3 abnormalities)\] in CR1 * AML ≥ CR2; patients should have \<5% marrow blasts at the time of transplant * High-risk ALL defined as: CR1 with high-risk cytogenetics t(9;22), t(8;14), t(4;11), t(1;19) for adult patients \>4 wk to achieve CR1 ≥ CR2 Patients should have \<5% marrow blasts at the time of transplant * MDS (\>int-1 per IPSS) after ≥ 1 prior cycle of induction chemotherapy; should have\<5% marrow blasts at the time of transplant * MM Stage II or III patients who have progressed after an initial response to chemotherapy or autologous HSCT or MM patients with refractory disease who may benefit from tandem autologous-nonmyeloablative allogeneic transplant * CLL, NHL or HD who are ineligible for autologous HSCT or who have resistant/refractory disease and who may benefit from tandem autologous nonmyeloablative allogeneic transplant. * Patients who have received a prior allogeneic HSCT and who have either rejected their grafts or who have become tolerant of their grafts with no active GvHD requiring immunosuppressive therapy could be enrolled Exclusion Criteria: * Patients with suitably matched related or unrelated donors * Patients with conventional transplant options (a conventional transplant should be the priority for eligible patients ≤ 50 yr of age …